1,1-dimethylethyl 6-[(3S)-3-{[(6-chloro-2-naphthalenyl)sulfonyl]amino}-2-oxo-1-pyrrolidinyl]-5-fluoro-3,4-dihydro-2(1H)-isoquinolinecarboxylate | 912846-59-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,1-dimethylethyl 6-[(3S)-3-{[(6-chloro-2-naphthalenyl)sulfonyl]amino}-2-oxo-1-pyrrolidinyl]-5-fluoro-3,4-dihydro-2(1H)-isoquinolinecarboxylate
• 英文别名: 1,1-Dimethylethyl 6-((3S)-3-{[(6-chloro-2-naphthalenyl)sulfonyl]amino}-2-oxo-1-pyrrolidinyl)-5-fluoro-3,4-dihydro-2(1H)-isoquinolinecarboxylate；tert-butyl 6-[(3S)-3-[(6-chloronaphthalen-2-yl)sulfonylamino]-2-oxopyrrolidin-1-yl]-5-fluoro-3,4-dihydro-1H-isoquinoline-2-carboxylate
• CAS: 912846-59-4
• 化学式: C₂₈H₂₉ClFN₃O₅S
• 分子量: 574.073
• InChiKey: ISTJCSIVCAHHOU-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  104
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl 6-[(3S)-3-{[(6-chloro-2-naphthalenyl)sulfonyl]amino}-2-oxo-1-pyrrolidinyl]-5-fluoro-3,4-dihydro-2(1H)-isoquinolinecarboxylate 在 盐酸 作用下， 以 甲醇 为溶剂， 生成 6-Chloro-N-[(3s)-1-(5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-6-Yl)-2-Oxo-Pyrrolidin-3-Yl]naphthalene-2-Sulfonamide
  参考文献：
  名称：

  The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs

  摘要：

  The discovery and evaluation of potent and long-acting oral sulfonamidopyrrolidin-2-one factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs are described. Unexpected selectivity issues versus tissue plasminogen activator in the former series were addressed in the later, delivering a robust candidate for progression towards clinical studies. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.129
• 作为产物：
  描述：

  2-(3,4-二氟苯基)乙胺 在 吡啶 、 四磷十氧化物 、 20 % Pd(OH)2/C 、 硼烷 、 氨 、 氢气 、 caesium carbonate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 碘甲烷 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 生成 1,1-dimethylethyl 6-[(3S)-3-{[(6-chloro-2-naphthalenyl)sulfonyl]amino}-2-oxo-1-pyrrolidinyl]-5-fluoro-3,4-dihydro-2(1H)-isoquinolinecarboxylate
  参考文献：
  名称：

  The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs

  摘要：

  The discovery and evaluation of potent and long-acting oral sulfonamidopyrrolidin-2-one factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs are described. Unexpected selectivity issues versus tissue plasminogen activator in the former series were addressed in the later, delivering a robust candidate for progression towards clinical studies. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.129

文献信息

• 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors
  申请人：Harling John David

  公开号：US20090099231A1

  公开（公告）日：2009-04-16

  The present invention provides pyrrolidinone derivatives as Factor Xa inhibitors and pharmaceutical compositions comprising the same. The invention also relates to processes for the preparation of such compounds, and the use of such compounds in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  本发明提供吡咯烷酮衍生物作为因子Xa抑制剂，以及包含这些衍生物的药物组合物。本发明还涉及制备这些化合物的方法，以及在医学中使用这些化合物，特别是在改善需要因子Xa抑制剂的临床病况方面的使用。
• The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs
  作者：Nigel S. Watson、Carl Adams、David Belton、David Brown、Cynthia L. Burns-Kurtis、Laiq Chaudry、Chuen Chan、Máire A. Convery、David E. Davies、Anne M. Exall、John D. Harling、Stephanie Irvine、Wendy R. Irving、Savvas Kleanthous、Iain M. McLay、Anthony J. Pateman、Angela N. Patikis、Theresa J. Roethke、Stefan Senger、Gary J. Stelman、John R. Toomey、Robert I. West、Caroline Whittaker、Ping Zhou、Robert J. Young

  DOI：10.1016/j.bmcl.2011.01.129

  日期：2011.3

  The discovery and evaluation of potent and long-acting oral sulfonamidopyrrolidin-2-one factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs are described. Unexpected selectivity issues versus tissue plasminogen activator in the former series were addressed in the later, delivering a robust candidate for progression towards clinical studies. (C) 2011 Elsevier Ltd. All rights reserved.